Group psychedelic therapy: empirical estimates of cost-savings and improved access

Group psychedelic therapy: empirical estimates of cost-savings and improved access

ObjectiveTo compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access.MethodsUsing 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psiloc...

Full description

Bibliographic Details
Main Authors: Elliot Marseille, Christopher S. Stauffer, Manish Agrawal, Paul Thambi, Kimberly Roddy, Michael Mithoefer, Stefano M. Bertozzi, James G. Kahn
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Psychiatry
Subjects:
psychedelic-assisted therapy
MDMA
psilocybin
economics
cost
access
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1293243/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1293243/full

Similar Items